Navigation Links
US Oncology Named to FORTUNE Magazine's World's Most Admired Companies List for Fifth Time

THE WOODLANDS, Texas, March 5 /PRNewswire/ -- US Oncology, Inc., the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care, has been named to FORTUNE magazine's World's Most Admired Companies list for 2010. The company ranks second in the Health Care: Pharmacy and Other category, up from third place in 2009. This is the fifth time US Oncology has been honored with FORTUNE magazine's World's Most Admired Companies distinction, having been named to the list in 2003, 2004, 2007, and 2009.

The magazine's annual list is considered the definitive report card on corporate reputations. Ranked by top industry executives and financial analysts on nine areas of leadership, US Oncology placed first in the categories of People Management and Social Responsibility, and second in its sector in the categories of Innovation, Use of Corporate Assets, and Quality of Management. The company ranks in the top five of eight categories, including Long-Term Investment (ranked 3), Quality of Product Services and Global Competitiveness (ranked 5).

US Oncology uses its expertise, insight and passion for eradicating cancer to develop innovative solutions that advance the quality and cost-effectiveness of cancer care. Through the use of technology, research, world-class evidence-based pathways, and patient education and support, the company works with physicians, patients, payers and the medical industry to improve patients' lives and advance the science and value of cancer care; and enables physicians to deliver this high quality care in the communities where patients live.

About US Oncology

US Oncology, Inc. is the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology provides a broad range of solutions to community oncologists, patients, payers, and the medical industry across all phases of the cancer care research and delivery system, and deploys innovation, technology, research and the use of evidence-based medicine and shared best practices to improve patient outcomes and offer a better patient experience. For more information, visit

SOURCE US Oncology, Inc.

Back to top



SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
2. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
3. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
4. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. US Oncology Announces Retirement of General Counsel Phil Watts
7. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
8. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
9. MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board
10. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
Breaking Biology News(10 mins):